Related references
Note: Only part of the references are listed.Randomized, controlled trial of telcagepant over four migraine attacks
Andrew P. Ho et al.
CEPHALALGIA (2010)
Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist
Christopher A. Salvatore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist
Ian M. Bell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Randomized, controlled trial of telcagepant for the acute treatment of migraine
K. M. Connor et al.
NEUROLOGY (2009)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Calcitonin gene-related peptide (CGRP) antagonists and migraine - Is this a new era?
Peter J. Goadsby
NEUROLOGY (2008)
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
T. W. Ho et al.
NEUROLOGY (2008)
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
David W. Dodick et al.
CNS DRUGS (2007)
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches
PJ Goadsby
DRUGS (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment:: a meta-analysis of 53 trials
MD Ferrari et al.
LANCET (2001)